NCT02498613 2025-09-25
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Proacta, Incorporated
Siemens Molecular Imaging